Predicting response to immunotherapy in melanoma patients
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
Hospices Civils de Lyon · NCT05527795
This study is trying to find out which features in melanoma patients can help predict how well they will respond to immunotherapy after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon (other) |
| Drugs / interventions | immunotherapy, Nivolumab, Ipilimumab |
| Locations | 1 site (Pierre-Bénite) |
| Trial ID | NCT05527795 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify clinical features that predict responses to adjuvant immunotherapy in patients with stage II, III, and IV resected melanoma. It will analyze the frequency and duration of responses to treatment, types of relapses, and overall survival rates based on clinical characteristics. By utilizing biological samples from patients treated between 2019 and 2029, the study seeks to enhance understanding of which patients are likely to benefit from immunotherapy and to uncover mechanisms of resistance.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with stage II, III, or IV resected melanoma who have undergone surgery and received adjuvant immunotherapy.
Not a fit: Patients under 18 years old or those who oppose participation in the study will not benefit from this research.
Why it matters
Potential benefit: If successful, this study could help identify melanoma patients who are most likely to benefit from adjuvant immunotherapy, potentially improving treatment outcomes.
How similar studies have performed: Other studies have shown success in identifying predictive markers for immunotherapy responses, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with stage II, III or IV (resected) melanoma * Treated by surgery and adjuvant immunotherapy between January 1st of 2019 and January 1st of 2029 * Gave informed consent to allow the use of biological samples for research purpose * Has read the information sheet regarding this study * With tumor samples available at the biobank center Exclusion Criteria: * Patients under 18 years old * Patients placed under the judicial protection * Opposed to this study
Where this trial is running
Pierre-Bénite
- Centre Hospitalier Lyon Sud — Pierre-Bénite, France (RECRUITING)
Study contacts
- Study coordinator: Stéphane Dalle, PhD
- Email: stephane.dalle@chu-lyon.fr
- Phone: +(33)478861679
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Melanoma, adjuvant immunotherapy